Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance

(Updated - October 19, 2021 6:28 AM EDT)

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.60, $0.24 better than the analyst estimate of $2.36. Revenue for the quarter came in at $23.3 billion versus the consensus estimate of $23.74 billion.

GUIDANCE:

Johnson & Johnson sees 2021 EPS of $9.77-$9.82, versus the consensus of $9.66. Johnson & Johnson sees 2021 revenue of $94.1-94.6 billion, versus the consensus of $94.3 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04